SB-007 addresses the root cause of Stargardt disease with the potential to treat all patients across all ABCA4 mutations SB-007 is the first dual AAV gene therapy in clinical development for Stargardt ...
The initiation of this study with the dual AAV vector gene therapy, SB-007, represents a critical advancement in finding a potential treatment option for patients with this disease. It is a ...
SB-007 addresses the root cause of Stargardt disease with the potential to treat all patients across all ABCA4 mutations SB-007 is the first dual AAV gene therapy in clinical development for ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback